既往生物制剂暴露对奥扎莫德在3期True North临床试验中疗效与安全性的影响
该分析纳入True North研究及其开放标签扩展中376例既往生物制剂暴露的溃疡性结肠炎患者,评估奥扎莫德疗效与安全性。结果显示,无论既往生物制剂数量或类型,奥扎莫德诱导期临床应答率均高于安慰剂,且疗效在52周及开放标签扩展中持久,未观察到新安全性信号,但这类患者可能需要更长时间应答。
要点
- 既往生物制剂暴露的溃疡性结肠炎患者中,奥扎莫德诱导期临床应答率高于安慰剂。
- 使用1种既往生物制剂的患者疗效高于使用≥2种者,52周疗效在各亚组相似。
- 奥扎莫德疗效在持续治疗约3年中持久,未观察到新安全性信号。
核心结论
- 奥扎莫德在既往生物制剂暴露的溃疡性结肠炎患者中有效且安全,但这类患者可能需要更多时间才能应答。
研究设计与样本
- True North为随机、安慰剂对照52周试验(10周诱导期、42周维持期),符合条件患者可进入开放标签扩展。
- 本分析纳入376例既往生物制剂暴露的溃疡性结肠炎患者。
主要发现
- 在安慰剂对照队列中,无论既往生物制剂数量或类型,奥扎莫德组第10周达到临床应答的患者均多于安慰剂组。
- 使用1种 vs ≥2种既往生物制剂的患者达到更高的疗效率。
- 第52周疗效率高于第10周,且无论既往生物制剂数量或类型各亚组相似。
- 奥扎莫德组 vs 安慰剂组达到症状应答(第5周,P=0.0173)和症状缓解(第10周,P=0.0207)的患者比例显著更高。
- 进入开放标签扩展的既往生物制剂暴露第10周奥扎莫德无应答者中,61%在额外10周奥扎莫德治疗后达到症状应答。
关键数值与推荐
- 进入开放标签扩展的既往生物制剂暴露第52周临床应答者中,奥扎莫德疗效在持续治疗约3年中持久。
- 未观察到新安全性信号。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with ulcerative colitis (UC) and prior biologic failure may have reduced or delayed efficacy with subsequent advanced therapies. This analysis evaluated the efficacy and safety of ozanimod during the True North (TN) study and its open-label extension (OLE) in biologic-exposed patients with UC. METHODS: TN was a randomized, placebo-controlled 52-week trial (10-week induction, 42-week maintenance period). Eligible patients could enter the OLE. Clinical outcomes were assessed at TN week (W) 10 and W52 and OLE W46 and W94. Symptomatic efficacy was evaluated through induction and in the OLE until W94. Safety was assessed. RESULTS: This analysis included 376 biologic-exposed patients. In the placebo-controlled cohort, more ozanimod-treated patients achieved clinical response than placebo at W10 regardless of the number or type of prior biologics; patients who used 1 vs ≥2 prior biologics achieved higher efficacy rates. Efficacy rates were higher at W52 than W10 and were similar across subgroups regardless of the number or type of prior biologics. Significantly greater proportions of ozanimod vs placebo patients achieved symptomatic response by W5 ( P = 0.0173) and symptomatic remission by W10 ( P = 0.0207). Among biologic-exposed TN W10 ozanimod nonresponders who entered the OLE, 61% achieved symptomatic response with an extra 10 weeks of ozanimod treatment. Ozanimod efficacy was durable for ∼3 years of continuous treatment in biologic-exposed W52 clinical responders who entered the OLE. No new safety signals were observed. DISCUSSION: Ozanimod was effective and safe in biologic-exposed patients with UC, but these patients may require more time to respond to treatment. Clinical trial registry website and trial numbers: ClinicalTrials.gov , numbers NCT02435992 and NCT02531126.
引用
- Sands BE, Rubin DT, Loftus EV, et al. Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial. Am J Gastroenterol. 2025. PMID: 39773524. doi:10.14309/ajg.0000000000003310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。